

Antonio Mazzocca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7631704/publications.pdf>

Version: 2024-02-01

33
papers

833
citations

471371

17
h-index

501076

28
g-index

34
all docs

34
docs citations

34
times ranked

1149
citing authors

#	ARTICLE	IF	CITATIONS
1	T(14;18) translocation in chronic hepatitis C virus infection. <i>Hepatology</i> , 2000, 31, 474-479.	3.6	157
2	Tumor-secreted lysophosphatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. <i>Hepatology</i> , 2011, 54, 920-930.	3.6	122
3	Lysophosphatidic Acid Receptor LPAR6 Supports the Tumorigenicity of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2015, 75, 532-543.	0.4	49
4	Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 607-617.	1.8	41
5	Sorafenib: 10 years after the first pivotal trial. <i>Future Oncology</i> , 2015, 11, 1863-1880.	1.1	40
6	Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ TÀcells. <i>Cell Reports</i> , 2021, 37, 110013.	2.9	38
7	The Metastatic Process: Methodological Advances and Pharmacological Challenges. <i>Current Medicinal Chemistry</i> , 2009, 16, 1704-1717.	1.2	33
8	New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. <i>Journal of Controlled Release</i> , 2017, 268, 184-197.	4.8	33
9	Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC. <i>Molecular Cancer</i> , 2009, 8, 29.	7.9	28
10	Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. <i>Thrombosis Research</i> , 2021, 198, 139-150.	0.8	27
11	Implications of the lysophosphatidic acid signaling axis in liver cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 277-282.	3.3	23
12	The Systemicâ€“Evolutionary Theory of the Origin of Cancer (SETOC): A New Interpretative Model of Cancer as a Complex Biological System. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4885.	1.8	22
13	Novel lysophosphatidic acid receptor 6 antagonists inhibit hepatocellular carcinoma growth through affecting mitochondrial function. <i>Journal of Molecular Medicine</i> , 2020, 98, 179-191.	1.7	22
14	1H-NMR metabolomics reveals a multitarget action of <i>Crithmum maritimum</i> ethyl acetate extract in inhibiting hepatocellular carcinoma cell growth. <i>Scientific Reports</i> , 2021, 11, 1259.	1.6	19
15	Growth Inhibition by the Farnesyltransferase Inhibitor FTI-277 Involves Bcl-2 Expression and Defective Association with Raf-1 in Liver Cancer Cell Lines. <i>Molecular Pharmacology</i> , 2003, 63, 159-166.	1.0	18
16	Circadian rhythms: a possible new player in non-alcoholic fatty liver disease pathophysiology. <i>Journal of Molecular Medicine</i> , 2019, 97, 741-759.	1.7	18
17	Inhibition of Hepatocellular Carcinoma Growth by Ethyl Acetate Extracts of Apulian Brassica oleracea L. and <i>Crithmum maritimum</i> L.. <i>Plant Foods for Human Nutrition</i> , 2020, 75, 33-40.	1.4	18
18	Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond. <i>Future Oncology</i> , 2015, 11, 2263-2266.	1.1	17

#	ARTICLE	IF	CITATIONS
19	Treatment of liver cancer cells with ethyl acetate extract of <i>Crithmum maritimum</i> permits reducing sorafenib dose and toxicity maintaining its efficacy. <i>Journal of Pharmacy and Pharmacology</i> , 2021, 73, 1369-1376.	1.2	16
20	DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer. <i>Cancer Research</i> , 2021, 81, 2861-2873.	0.4	15
21	A systemic evolutionary approach to cancer: Hepatocarcinogenesis as a paradigm. <i>Medical Hypotheses</i> , 2016, 93, 132-137.	0.8	13
22	Moving the systemic evolutionary approach to cancer forward: Therapeutic implications. <i>Medical Hypotheses</i> , 2018, 121, 80-87.	0.8	13
23	Chronic Inflammation in Obesity and Cancer Cachexia. <i>Journal of Clinical Medicine</i> , 2022, 11, 2191.	1.0	10
24	Xanthenylacetic Acid Derivatives Effectively Target Lysophosphatidic Acid Receptor 6 to Inhibit Hepatocellular Carcinoma Cell Growth. <i>ChemMedChem</i> , 2021, 16, 2121-2129.	1.6	9
25	Autotaxin is a novel molecular identifier of type I endometrial cancer. <i>Medical Oncology</i> , 2018, 35, 157.	1.2	8
26	The Edible Plant <i>Crithmum maritimum</i> Shows Nutraceutical Properties by Targeting Energy Metabolism in Hepatic Cancer. <i>Plant Foods for Human Nutrition</i> , 2022, 77, 481-483.	1.4	7
27	A distinctive protein signature induced by lysophosphatidic acid receptor 6 (LPAR6) expression in hepatocellular carcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2020, 526, 1150-1156.	1.0	5
28	New hypotheses for cancer generation and progression. <i>Medical Hypotheses</i> , 2021, 152, 110614.	0.8	4
29	Reply. <i>Hepatology</i> , 2013, 57, 418-419.	3.6	1
30	Hepatocellular Carcinoma as a Paradigm for a Systemic Evolutionary Approach to Cancer. , 2016, , 157-161.		1
31	The perplexity of targeting genetic alterations in hepatocellular carcinoma. <i>Medical Oncology</i> , 2020, 37, 67.	1.2	1
32	Abstract 4217: Engaging CD151 inhibits cell migration and metastasis through a novel mechanism involving the cell adhesion molecule ALCAM/CD166. , 2012, , .		0
33	Metastatic Secondary Anaplastic Meningioma. <i>Open Access Library Journal (oalib)</i> , 2016, 03, 1-6.	0.1	0